Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other financing activities (2018 - 2021)

Historic Other financing activities for ImmunityBio (IBRX) over the last 4 years, with Q3 2021 value amounting to -$1.2 million.

  • ImmunityBio's Other financing activities fell 62944.79% to -$1.2 million in Q3 2021 from the same period last year, while for Dec 2022 it was -$1.2 million, marking a year-over-year decrease of 18285.71%. This contributed to the annual value of $1.4 million for FY2021, which is N/A changed from last year.
  • Per ImmunityBio's latest filing, its Other financing activities stood at -$1.2 million for Q3 2021, which was down 62944.79% from $2.6 million recorded in Q1 2021.
  • In the past 5 years, ImmunityBio's Other financing activities registered a high of $2.6 million during Q1 2021, and its lowest value of -$1.2 million during Q3 2021.
  • In the last 4 years, ImmunityBio's Other financing activities had a median value of $40000.0 in 2019 and averaged $182375.0.
  • Data for ImmunityBio's Other financing activities shows a peak YoY increase of 203333.33% (in 2021) and a maximum YoY decrease of 62944.79% (in 2021) over the last 5 years.
  • ImmunityBio's Other financing activities (Quarter) stood at $50000.0 in 2018, then crashed by 232.0% to -$66000.0 in 2019, then plummeted by 146.97% to -$163000.0 in 2020, then tumbled by 629.45% to -$1.2 million in 2021.
  • Its Other financing activities was -$1.2 million in Q3 2021, compared to $2.6 million in Q1 2021 and -$163000.0 in Q3 2020.